68 reports

  • 2.1 PARKINSON'S MARKET FORECAST TO REACH $8.8B BY 2026
  • 12.2 ABBREVIATIONS

PRX-## IS A MONOCLONAL ANTIBODY (MAB) TARGETING THE Α-SYNUCLEIN PROTEIN, PREVENTING THEIR AGGREGATION AND POTENTIALLY HALTING DISEASE PROGRESSION.

  • Psychotic Disorder
  • Forecast
  • Adamas Pharmaceuticals, Inc.
  • Impax Laboratories, Inc.
  • Kyowa Hakko Kirin Co., Ltd.

At present days, neurodegenerative diseases represent one of the main causes of death in the industrialized economy.

  • Dementia
  • Mental Health
  • Psychotic Disorder
  • Therapy
  • World
  • Effexor

SOLANEZUMAB Solanezumab is a monoclonal antibody directed against Aβ##-##.

  • Hospital
  • Psychotic Disorder
  • AstraZeneca PLC
  • Lilly Endowment Inc.
  • Pfizer Inc.

One such trend is the emergence of biomarkers.

  • Psychotic Disorder
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • 6.3 Pipeline Programs Targeting Microtubule-Associated Protein Tau for Parkinson's Disease

The terms of the latest agreement state that Voyager will perform research and preclinical development work to vectorize antibodies directed against α-synuclein that are designated by AbbVie, after which AbbVie may select one or more vectorized antibodies to advance into I

  • Mental Health
  • Psychotic Disorder
  • World
  • AbbVie Inc.
  • BioMedica Inc.
  • Parkinson's Disease Market, Global, Co-development Deals by Molecule type
  • Parkinson's Disease Market, Global, Licensing Deals by Molecule Type and

Other molecule types included in co-development deals were gene therapies, peptides, monoclonal antibody (mAb) therapies and oligonucleotides, but their presence is significantly less prominent.

  • Psychotic Disorder
  • Forecast
  • Addex Therapeutics Ltd
  • Novartis AG
  • Parkinson Study Group

It is an anti-CGRP humanized monoclonal antibody.

  • Psychotic Disorder
  • United States
  • Auspex Pharmaceuticals, Inc.
  • Cephalon, Inc.
  • ChemGenex Pharmaceuticals Limited
  • GBIHC414MR / Published SEP 2016 Page 184
  • GBIHC414MR / Published SEP 2016 Page 185

Human monoclonal antibodies against amyloid-beta from healthy adults.

  • Psychotic Disorder
  • Therapy
  • Company
  • Company Financials
  • Forecast

The H##L## Mice are capable of generating human monoclonal antibodies.

  • Psychotic Disorder
  • United States
  • genOway SA
  • Lexicon
  • Taconic Farms, Inc.
  • BISPECIFIC MONOCLONAL ANTIBODIES TO INHIBIT SNCA FOR PARKINSON'S DISEASE - DRUG PROFILE
  • Licensing and Collaboration

Prasinezumab is an alpha-synuclein monoclonal antibody.

  • Monoclonal Antibody
  • Psychotic Disorder
  • United States
  • World
  • Product Initiative
  • JUN 19, 2018: PROTHENA ANNOUNCES PHASE 1B CLINICAL TRIAL RESULTS OF PRX002/RG7935 FOR PARKINSON'S DISEASE PUBLISHED IN JAMA NEUROLOGY
  • EQUITY OFFERING

The company develops monoclonal antibodies directed specifically at disease-causing proteins.

  • Psychotic Disorder
  • United States
  • World
  • Company Financials
  • Prothena Corporation plc
  • MONOCLONAL ANTIBODY TO INHIBIT ALPHA SYNUCLEIN FOR CENTRAL NERVOUS SYSTEM DISORDERS - DRUG PROFILE
  • PIPELINE BY PROMIS NEUROSCIENCES INC, H2 2018

PRX-## (RG##) is an alpha-synuclein monoclonal antibody.

  • Psychotic Disorder
  • Therapy
  • United States
  • World
  • Product Initiative

The molecules developed by Companies in Phase II, Phase I, IND/ CTA Filed, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Pharmaceutical
  • Psychotic Disorder
  • United States
  • World
  • Product Initiative

The company' s pipeline is strong with Siponimod or BAF## (sphingosine-##-phosphate (s##P) receptor modulator), an oral drug, which is expected to be launched during the forecast period, and secukinumab or AIN## (antiinterleukin-## monoclonal antibody) which is in Phas

  • Psychotic Disorder
  • Biogen Idec Inc.
  • Merck Serono S.A.
  • Novartis AG
  • Pfizer Inc.
  • BISPECIFIC MONOCLONAL ANTIBODIES TO INHIBIT SNCA FOR PARKINSON'S DISEASE - DRUG PROFILE
  • Licensing and Collaboration

Prasinezumab is an alpha-synuclein monoclonal antibody.

  • Immunotherapy
  • Psychotic Disorder
  • Therapy
  • United States
  • Product Initiative
  • PARTNERSHIPS
  • EQUITY OFFERING

The company develops monoclonal antibodies directed specifically at disease-causing proteins.

  • Psychotic Disorder
  • United States
  • World
  • Company
  • Prothena Corporation plc
  • LICENSING AGREEMENTS

Its products under clinical development include Selincro, an opioid receptor ligand; Tozadenant, an innovative A##a antagonist; SYN##, a selective ##-HT## receptor antagonist; and BTT##, a monoclonal antibody, among others.

  • Psychotic Disorder
  • Therapy
  • United States
  • Company Financials
  • Acorda Therapeutics, Inc.
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Denali Therapeutics Inc, H2 2017
  • ANTIBODY TO INHIBIT ALPHA SYNUCLEIN FOR PARKINSON'S DISEASE AND MULTIPLE SYSTEM ATROPHY - DRUG PROFILE

NA : Not Available Source: Global Markets Direct Other Developmental Activities ANTIBODY TO INHIBIT ALPHA SYNUCLEIN FOR PARKINSON' S DISEASE AND MULTIPLE SYSTEM ATROPHY - DRUG PROFILE CS-##BR## - DRUG PROFILE ENT-## - DRUG PROFILE MONOCLONAL ANTIBODY TO INHIBIT ALPHA S

  • Neurological Disorder
  • Psychotic Disorder
  • United States
  • World
  • Product Initiative
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Denali Therapeutics Inc, H1 2018
  • ANTIBODY TO INHIBIT ALPHA SYNUCLEIN FOR PARKINSON'S DISEASE AND MULTIPLE SYSTEM ATROPHY - DRUG PROFILE

NA : Not Available Source: Global Markets Direct MONOCLONAL ANTIBODY TO INHIBIT ALPHA SYNUCLEIN FOR CENTRAL NERVOUS SYSTEM DISORDERS - DRUG PROFILE NPT-## - DRUG PROFILE In December 2010, Neuropore Therapies, Inc filed a patent with application (US##/ ##, ##) entitled Compo

  • Neurological Disorder
  • Psychotic Disorder
  • Therapy
  • United States
  • Product Initiative

The company' s biomarker products comprise Elisa kits, recombinant proteins and calibrants, and monoclonal antibodies.

  • Clinical Trial
  • Hospital
  • Mental Health
  • Psychotic Disorder
  • AutoGenomics, Inc.

Most recently she served as the Worldwide Brand Director at Novartis Pharmaceuticals Corporation, where she was the global launch lead for Aimovig®, the first monoclonal antibody approved by the U. S.

  • Clinical Trial
  • HIV AIDS
  • Psychotic Disorder
  • United States
  • AcelRx Pharmaceuticals, Inc.

MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications.

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • United Kingdom
  • Heptares Therapeutics Limited
  • MONOCLONAL ANTIBODY TO INHIBIT ALPHA SYNUCLEIN FOR CENTRAL NERVOUS SYSTEM DISORDERS - DRUG PROFILE
  • PARKINSON'S DISEASE - PIPELINE BY PROMIS NEUROSCIENCES INC, H1 2018

PRX-## (RG##) IS AN ALPHA-SYNUCLEIN MONOCLONAL ANTIBODY.

  • Cell Therapy
  • Psychotic Disorder
  • United States
  • Company
  • Anavex Life Sciences Corp.

This agreement enables companies to provide monoclonal antibody therapeutics for the treatment of neurodegenerative disease.

  • Psychotic Disorder
  • Therapy
  • United States
  • Company
  • Denali Therapeutics Inc.
  • May 12, 2016: Biotie Interim Report 1 January - 31 March 2016

BTT## is a fully human monoclonal antibody that specifically binds to vascular adhesion protein ## (VAP-##), an endothelial cell adhesion receptor expressed on blood vessels.

  • Psychotic Disorder
  • Therapy
  • United States
  • Company
  • Biotie Therapies Corp.
  • PIPELINE BY AEVI GENOMIC MEDICINE INC, H2 2018
  • Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Companies Involved in Therapeutics Development

Aevi' s product candidate AEVI-##, is an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn' s disease.

  • Psychotic Disorder
  • Therapy
  • United States
  • World
  • Product Initiative
  • Mar 14, 2018: Voyager Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
  • Financial Announcements

VY- TAU## is an adeno-associated virus (AAV) vectorized version of an anti-tau monoclonal antibody for direct one-time delivery to the CNS.

  • Psychotic Disorder
  • Therapy
  • United States
  • Company
  • Voyager Therapeutics, Inc.

This agreement enables BiocerOX and Janssen Pharma to develop a monoclonal antibody directed at an immune checkpoint modulator; and allows Bioceros to generate IP to protect high value therapeutic monoclonal antibodies and sell such antibodies.

  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • United States
  • Janssen Biotech, Inc.
  • PIPELINE BY AEVI GENOMIC MEDICINE INC, H2 2018

Aevi' s product candidate AEVI-##, is an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn' s disease.

  • Psychotic Disorder
  • United States
  • World
  • Product Initiative
  • Addex Therapeutics Ltd

MONOCLONAL ANTIBODY ACTS AS FOLLICLE STIMULATING HORMONE RECEPTOR ANTAGONIST.

  • Obesity
  • Pharmaceutical
  • Psychotic Disorder
  • Therapy
  • Omeros Corporation